A detailed history of Woodline Partners LP transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 2,341,121 shares of CLDX stock, worth $61.8 Million. This represents 0.72% of its overall portfolio holdings.

Number of Shares
2,341,121
Previous 757,771 208.95%
Holding current value
$61.8 Million
Previous $28 Million 183.57%
% of portfolio
0.72%
Previous 0.28%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$32.06 - $44.56 $50.8 Million - $70.6 Million
1,583,350 Added 208.95%
2,341,121 $79.5 Million
Q2 2024

Aug 14, 2024

BUY
$32.76 - $42.56 $219,852 - $285,620
6,711 Added 0.89%
757,771 $28 Million
Q1 2024

May 15, 2024

BUY
$35.22 - $51.88 $12.8 Million - $18.9 Million
363,408 Added 93.75%
751,060 $31.5 Million
Q4 2023

Feb 14, 2024

BUY
$22.61 - $40.65 $6.33 Million - $11.4 Million
280,156 Added 260.62%
387,652 $15.4 Million
Q3 2023

Nov 14, 2023

BUY
$25.45 - $37.46 $1.35 Million - $1.99 Million
52,997 Added 97.24%
107,496 $2.96 Million
Q2 2023

Aug 14, 2023

SELL
$30.29 - $38.28 $29,441 - $37,208
-972 Reduced 1.75%
54,499 $1.85 Million
Q1 2023

May 15, 2023

BUY
$34.78 - $47.43 $1.93 Million - $2.63 Million
55,471 New
55,471 $2 Million
Q2 2022

Aug 15, 2022

SELL
$20.5 - $37.33 $10.6 Million - $19.2 Million
-514,738 Reduced 88.87%
64,454 $1.74 Million
Q1 2022

May 16, 2022

BUY
$27.64 - $39.32 $8.83 Million - $12.6 Million
319,297 Added 122.86%
579,192 $19.7 Million
Q4 2021

Feb 14, 2022

BUY
$35.68 - $56.27 $9.27 Million - $14.6 Million
259,895 New
259,895 $10 Million

Others Institutions Holding CLDX

About Celldex Therapeutics, Inc.


  • Ticker CLDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,772,400
  • Market Cap $1.23B
  • Description
  • Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...
More about CLDX
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.